{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-027594","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.043666+00:00","generated_at":"2026-06-18T16:06:55.544535+00:00","sec_items":["5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anzu SPAC extends deadline to Sept 30, 2023; ~$387.5M redeemed, trust drops to $45.2M","bullets":["Stockholders approved extension of business combination deadline from March 4, 2023 to September 30, 2023.","38,187,226 public shares redeemed for ~$387.5 million ($10.15 per share).","Post-redemption: 4,312,774 public shares outstanding and $45.2 million remaining in trust.","Extension vote: 36,753,901 for, 6,216,334 against; quorum of 42,970,235 shares (80.89%).","Adjournment proposal was approved but not needed given extension passage."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-027594","json":"https://secwatch.observer/filing/0001104659-23-027594.json","markdown":"https://secwatch.observer/filing/0001104659-23-027594.md","text":"https://secwatch.observer/filing/0001104659-23-027594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000110465923027594/0001104659-23-027594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000110465923027594/tm238204d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T16:06:55.544535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b87a2d09b6a586f04b111e4c48f9805a12582fa0","claim":"Envoy Medical, Inc. shareholders rejected Adjournment Proposal: adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies at the 2023-02-28 meeting.","evidence_excerpt":"Proposal No. 2 - The Adjournment Proposal – The stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Stockholder Meeting, there are insufficient shares Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the Special Meeting or at the time of the Special Meeting to approve the Extension Amendment Proposal or if the Maximum Redemption Condition (as defined in the Proxy Statement) is not met and is not waived by the Board in its sole discretion (the “ Adjournment Proposal ”). Passage of the Adjournment Proposal required a majority of the Company’s outstanding shares of Common Stock. The voting results were as follows: For Against Abstain 38,984,445 3,985,790 0 Although the Adjournment Proposal received sufficient votes to be approved, it was not presented for adoption and no mo","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000110465923027594/0001104659-23-027594-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-02-28"}],"fact_type":"shareholder_vote"},{"claim_id":"dd48e922c631bfa986b0fd7eb8749de7fe3ea29a","claim":"Envoy Medical, Inc. shareholders approved Extension Amendment Proposal: amend the amended and restated certificate of incorporation to extend the date by which the Company has to consummate an initial business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Board at the 2023-02-28 meeting.","evidence_excerpt":"Proposal No. 1 - The Extension Amendment Proposal – The stockholders approved a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate an initial business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Board (the “ Extension Amendment Proposal ”). Passage of the Extension Amendment Proposal required approval by the affirmative vote of at least 65% of the Company’s issued and outstanding shares of Common Stock. The voting results were as follows: For Against Abstain 36,753,901 6,216,334 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000110465923027594/0001104659-23-027594-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}